

FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2022

<https://marketpublishers.com/r/F000AEC9526DEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: F000AEC9526DEN

Abstracts

This report can be delivered to the clients within 48 hrs

DelveInsight's, "FTase (Farnesyltransferase) inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

FTASE inhibitor Understanding

FTase inhibitor: Overview

Farnesyltransferase (FTase) is a heterodimeric zinc enzyme that belongs to the transferases family. It catalyzes the synthesis of geranylgeranyl diphosphate from Trans, trans-farnesyl diphosphate and isopentenyl diphosphate. Protein farnesyltransferase (FTase) is a two-subunit enzyme that is comprised by a 48 kDa α -subunit and a 46 kDa β -subunit.

FTase catalyzes the post-translational addition of a hydrophobic isoprenoid farnesyl moiety from farnesyl diphosphate (FPP), to a cysteine residue of a protein substrate

containing a typical CAAX motif at the carboxyl terminus.

FTase Inhibitors- Farnesyltransferase inhibitors hold considerable promise as anticancer drugs in the clinical studies. Several studies evaluated including the identification of natural products such as the chaetomelic and zaragozic acids that mimic farnesylpyrophosphate, bisubstrate transition state analogs combining elements of the farnesyl and tetrapeptide substrates and peptidomimetics that reproduce features of the carboxyl terminal tetrapeptide CA1A2X sequence. Several farnesyl transferase inhibitors are in clinical development for the treatment of solid tumors.

FTase inhibitor Emerging Drugs Chapters

This segment of the FTase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

FTase inhibitor Emerging Drugs

Tipifarnib: Kura Oncology

Tipifarnib is an oral investigational farnesyl transferase inhibitor. It is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase. By inhibiting the farnesylation of proteins, the molecule prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.

Lonafarnib: Eiger Biopharmaceuticals

Lonafarnib (also known as SCH66336) is a tricyclic nonpeptidic farnesyl transferase inhibitor that competes with protein substrates for binding to farnesyl transferase. It blocks the post-translational farnesylation of prelamin A and other proteins that are targets for farnesylation. Farnesylation is essential for the function of both mutant and non-mutant lamin-A proteins, including progerin. Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals.

Further product details are provided in the report.....

FTase inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different FTase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on FTase inhibitor

There are approx. 2+ key companies which are developing the FTase inhibitor. The companies which have their FTase inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Eiger Biopharmaceuticals.

Phases

DelveInsight's report covers around 2+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

FTase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

FTase inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I,

preclinical and discovery stage. It also analyses FTase inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging FTase inhibitor drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence FTase inhibitor R&D. The therapies under development are focused on novel approaches for FTase inhibitor.

FTase inhibitor Report Insights

FTASE inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

FTase inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing FTase inhibitor drugs?

How many FTase inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for FTase inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the FTase inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for FTase inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Kura Oncology

Eiger Biopharmaceuticals

Key Products

Tipifarnib

Lonafarnib

Contents

Introduction

Executive Summary

FTASE inhibitor: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

FTASE inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

FTASE inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

FTASE inhibitor Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tipifarnib: Kura Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
FTase inhibitor Key Companies
FTase inhibitor Key Products
FTase inhibitor- Unmet Needs
FTase inhibitor- Market Drivers and Barriers
FTase inhibitor- Future Perspectives and Conclusion
FTase inhibitor Analyst Views
FTase inhibitor Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for FTase inhibitor
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for FTase inhibitor
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: FTase (Farnesyltransferase) inhibitor– Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/F000AEC9526DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F000AEC9526DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970